Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 472 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

AstraZeneca to take over Omthera Pharmaceuticals

As per the deal, AstraZeneca will acquire Omthera for $12.70 per share, or approximately $323m, which has an Enterprise Value of approximately $260m after incorporating Omthera’s cash balances